AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37181803 — intervention group
Group type: COMPARATOR
Intervention: Fit-metabolically healthy (19.5%)
Number of subjects: 492
Study 37181803 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfit-metabolically healthy (29.9%)
Number of subjects: 492
Study 37181877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock Interview Rating Scale (MIRS)
Number of subjects: 90
Study 37181888 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral psilocybin (0.25 mg/kg)
Number of subjects: 30
Study 37181888 — intervention group
Group type: COMPARATOR
Intervention: Active placebo-control agent (250 mg of niacin)
Number of subjects: 30
Study 37181927 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of chronotype polygenic score
Number of subjects: 0
Study 37181927 — intervention group
Group type: COMPARATOR
Intervention: ChooseWell 365 intervention
Number of subjects: 0
Study 37181927 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotype polygenic score
Number of subjects: 0
Study 37181927 — intervention group
Group type: COMPARATOR
Intervention: Workplace healthy eating intervention
Number of subjects: 0
Study 37181931 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Diet Quality Score (GDQS) in the second tercile
Number of subjects: 0
Study 37181931 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein intake
Number of subjects: 0
Study 37181931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status and socioeconomic factors
Number of subjects: 0
Study 37181933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers-only arm
Number of subjects: 390
Study 37181933 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents-combined arm
Number of subjects: 390
Study 37181933 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal social support
Number of subjects: 390
Study 37181935 — intervention group
Group type: EXPERIMENTAL
Intervention: Food service staff training focused on Child and Adult Care Food Program (CACFP) best practices
Number of subjects: 9
Study 37181935 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-practice menu with healthy recipes
Number of subjects: 9
Study 37181934 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-fortified salt (QFS; iron, iodine, folic acid, vitamin B)
Number of subjects: 0
Study 37181936 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 egg/d for 6 months
Number of subjects: 489
Study 37182298 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert-based computerized decision support (CDS)
Number of subjects: 798
Study 37182298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 798
Study 37182434 — intervention group
Group type: COMPARATOR
Intervention: MA (160 mg orally daily)
Number of subjects: 180
Study 37182434 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 180
Study 37182434 — intervention group
Group type: COMPARATOR
Intervention: MA + LNG-IUS (MA 160 mg orally daily plus LNG-IUS)
Number of subjects: 180
Study 37182434 — intervention group
Group type: COMPARATOR
Intervention: MA
Number of subjects: 180
Study 37182529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed HPV self-collection kit with scheduling assistance
Number of subjects: 665
Study 37182529 — intervention group
Group type: COMPARATOR
Intervention: Scheduling assistance alone (control)
Number of subjects: 665
Study 37182534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam-durlobactam (1·0 g of each drug in combination over 3 h every 6 h for 7-14 days)
Number of subjects: 181
Study 37182534 — intervention group
Group type: COMPARATOR
Intervention: Colistin (2·5 mg/kg over 30 min every 12 h for 7-14 days)
Number of subjects: 181
Study 37182534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam-durlobactam
Number of subjects: 181
Study 37182534 — intervention group
Group type: COMPARATOR
Intervention: Colistin
Number of subjects: 181
Study 37182538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib plus letrozole or anastrozole
Number of subjects: 456
Study 37182538 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole or anastrozole
Number of subjects: 456
Study 37182692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric Ketogenic Diets (KDs)
Number of subjects: 199
Study 37182692 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of ketosis
Number of subjects: 199
Study 37182692 — intervention group
Group type: EXPERIMENTAL
Intervention: ß-Hydroxybutyrate (ßHB) plasma concentrations
Number of subjects: 199
Study 37182695 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal UIC ≥250 μg/L
Number of subjects: 469
Study 37182695 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal TSI >90th quantiles
Number of subjects: 469
Study 37182695 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal TSH ≥2.5 mIU/L
Number of subjects: 469
Study 37182704 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6WT)
Number of subjects: 50
Study 37182704 — intervention group
Group type: COMPARATOR
Intervention: Visual analogue scale (VAS)
Number of subjects: 50
Study 37182704 — intervention group
Group type: COMPARATOR
Intervention: Core outcome measure index (COMI)
Number of subjects: 50
Study 37182704 — intervention group
Group type: COMPARATOR
Intervention: Zurich claudication questionnaire (ZCQ)
Number of subjects: 50
Study 37182704 — intervention group
Group type: COMPARATOR
Intervention: Ceiling effect assessment
Number of subjects: 50
Study 37182818 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 20
Study 37183098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% i.v. at a dose of 1.5 mg/kg
Number of subjects: 140
Study 37183098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 37183103 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (≤2 years since chemotherapy completion)
Number of subjects: 36
Study 37183103 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 36
Study 37183103 — intervention group
Group type: COMPARATOR
Intervention: Overall cognition and memory
Number of subjects: 36
Study 37183104 — intervention group
Group type: EXPERIMENTAL
Intervention: EFICANCER individualized and supervised exercise program
Number of subjects: 90
Study 37183104 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard oncological care)
Number of subjects: 90
Study 37183115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine/Rituximab (BR)
Number of subjects: 0
Study 37183115 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine/Rituximab (CR)
Number of subjects: 0
Study 37183115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine/Rituximab (BR) with Acalabrutinib
Number of subjects: 0
Study 37183368 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Personality (PP; N=482)
Number of subjects: 996
Study 37183368 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Brings Change Project (ABC; N=514)
Number of subjects: 996
Study 37183454 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy for 24 weeks
Number of subjects: 770
Study 37183454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study 37183454 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (delayed: relugolix alone for 12 weeks, then combination for 12 weeks)
Number of subjects: 770
Study 37183520 — intervention group
Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg OD
Number of subjects: 111
Study 37183520 — intervention group
Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg BID
Number of subjects: 111
Study 37183520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 37183528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus chemotherapy (paclitaxel 200 mg/m2)
Number of subjects: 0
Study 37183528 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (paclitaxel 200 mg/m2)
Number of subjects: 0
Study 37183700 — intervention group
Group type: EXPERIMENTAL
Intervention: AVO algorithm (SmartDelay)
Number of subjects: 310
Study 37183700 — intervention group
Group type: COMPARATOR
Intervention: Fixed atrioventricular delay of 120 ms with biventricular pacing
Number of subjects: 310
Study 37183779 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib 60 mg single oral dose
Number of subjects: 6
Study 37183819 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT+P (Stereotactic Body Radiotherapy plus Pembrolizumab)
Number of subjects: 97
Study 37183819 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT+P
Number of subjects: 97
Study 37183819 — intervention group
Group type: EXPERIMENTAL
Intervention: High-RS (CD8+ T cell radiomics score)
Number of subjects: 97
Study 37183819 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated circulating IL-8
Number of subjects: 97
Study 37183837 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF (100 μg/kg body weight, maximum total dosage of 6 mg) administered once 24-48 hours following chemotherapy for two cycles
Number of subjects: 160
Study 37183837 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Number of subjects: 160
Study 37183871 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB) infusion
Number of subjects: 20
Study 37183871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 37183883 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 3364
Study 37183883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine phenylacetate
Number of subjects: 3364
Study 37183883 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 C-methacetin breath test (MBT)
Number of subjects: 3364
Study 37183883 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry
Number of subjects: 3364
Study 37184071 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37184136 — intervention group
Group type: EXPERIMENTAL
Intervention: Izokibep, a novel IL-17A neutralizing Affibody molecule, dosage and duration not specified
Number of subjects: 0
Study 37184216 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy amplitude-modulated electromagnetic field exposure (AutEMdev)
Number of subjects: 66
Study 37184292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal contraception
Number of subjects: 314704
Study 37184292 — intervention group
Group type: COMPARATOR
Intervention: Non-users of hormonal contraception
Number of subjects: 314704
Study 37184470 — intervention group
Group type: EXPERIMENTAL
Intervention: Different exercise modalities and intensities
Number of subjects: 0
Study 37184470 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37184523 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat ≤10 mg/d for 14 weeks
Number of subjects: 27
Study 37184602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Week CGM Home Test, Nocturnal Glucose Increments, and Standardized Liquid Mixed Meal Breakfasts
Number of subjects: 0
Study 37184615 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for criminal legal staff to address public stigma
Number of subjects: 0
Study 37184615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based acceptance and commitment therapy to address self-stigma
Number of subjects: 0
Study 37184828 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole QD
Number of subjects: 270
Study 37184828 — intervention group
Group type: COMPARATOR
Intervention: Vehicle QD
Number of subjects: 270
Study 37184839 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 14% gel with standard of care (SoC)
Number of subjects: 176
Study 37184839 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 14% gel with SoC
Number of subjects: 176
Study 37184839 — intervention group
Group type: COMPARATOR
Intervention: SoC only
Number of subjects: 176
Study 37184872 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus low-level stochastic vibrotactile stimulation (SVS) using a vibrating crib mattress with a 3-hour on-off cycle.
Number of subjects: 208
Study 37184872 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU).
Number of subjects: 208
Study 37184872 — intervention group
Group type: EXPERIMENTAL
Intervention: SVS (vibrating mattress).
Number of subjects: 208
Study 37184896 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based mHealth intervention
Number of subjects: 34
Study 37184905 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 37184905 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Relaxation
Number of subjects: 0
Study 37184905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37185188 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised pelvic floor muscle training (PFMT) with a home-based pressure-mediated biofeedback device
Number of subjects: 500
Study 37185188 — intervention group
Group type: COMPARATOR
Intervention: At-home pelvic floor muscle training (PFMT) alone
Number of subjects: 500
Study 37185191 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital technologies for motor rehabilitation
Number of subjects: 500
Study 37185193 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of levothyroxine treatment after a control period of 12 weeks, with gradual discontinuation and regular monitoring of thyroid function.
Number of subjects: 513
Study 37185193 — intervention group
Group type: COMPARATOR
Intervention: Control period of 12 weeks with continuous levothyroxine treatment.
Number of subjects: 513
Study 37185197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous remimazolam
Number of subjects: 150
Study 37185197 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 150
Study 37185231 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy-based sleep duration and continuity measures (24-hour and nocturnal sleep duration, sleep fragmentation index, sleep efficiency)
Number of subjects: 298
Study 37185231 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy-based sleep duration and continuity measures
Number of subjects: 298
Study 37185272 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-FGR infants
Number of subjects: 135
Study 37185596 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg OTO-104
Number of subjects: 174
Study 37185596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 37185640 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report diaries over 16 weeks
Number of subjects: 12
Study 37185649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary follow-up (nurse-based and pharmacist-based) for 2 years
Number of subjects: 1720
Study 37185649 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up
Number of subjects: 1720
Study 37185873 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (90 mg/m²)
Number of subjects: 1088
Study 37185873 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 1088
Study 37185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (sending glucose readings via smartphone application and monthly video calls)
Number of subjects: 106
Study 37185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 106
Study 37185903 — intervention group
Group type: COMPARATOR
Intervention: Standard care (routine monthly on-site visits)
Number of subjects: 106
Study 37185903 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 106
Study 37185921 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 155
Study 37185961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy (maintenance)
Number of subjects: 14836
Study 37185961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) with chemotherapy (maintenance)
Number of subjects: 14836
Study 37185961 — intervention group
Group type: EXPERIMENTAL
Intervention: TKIs with chemotherapy (maintenance)
Number of subjects: 14836
Study 37185961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy (maintenance) in platinum-sensitive EOC
Number of subjects: 14836
Study 37185961 — intervention group
Group type: EXPERIMENTAL
Intervention: TKIs with chemotherapy in platinum-sensitive EOC
Number of subjects: 14836
Study 37185961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy (maintenance) in platinum-resistant EOC
Number of subjects: 14836
Study 37185961 — intervention group
Group type: EXPERIMENTAL
Intervention: TKIs with chemotherapy in platinum-resistant EOC
Number of subjects: 14836
Study 37186034 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Number of subjects: 34
Study 37186034 — intervention group
Group type: COMPARATOR
Intervention: Control (physiotherapy with balance exercises only)
Number of subjects: 34
Study 37186063 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib 45 mg orally twice daily (bid) with Hydroxychloroquine 400 mg orally bid
Number of subjects: 9
Study 37186070 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 70
Study 37186070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 37186094 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at incremental rates up to 1.0 μg/kg/min
Number of subjects: 30
Study 37186094 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of phenylephrine infusion
Number of subjects: 30
Study 37186265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GnRH-agonist
Number of subjects: 150
Study 37186265 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone
Number of subjects: 150
Study 37186316 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe depressive symptoms (MSD, CESD-10 ≥10)
Number of subjects: 4153
Study 37186316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-severe depressive symptoms (Mild-SD, CESD-10 ≥5)
Number of subjects: 4153
Study 37186316 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social support (MOS-SSS <72)
Number of subjects: 4153
Study 37186357 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal electrical stimulation by interferential therapy (IFT)
Number of subjects: 0
Study 37186357 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 0
Study 37186574 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based exercise program
Number of subjects: 43
Study 37186577 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 21320
Study 37186577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21320
Study 37186584 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPSS-DM intervention
Number of subjects: 66
Study 37186584 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 66
Study 37186772 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training during a standardized pulmonary rehabilitation program (5 days a week for 4 weeks)
Number of subjects: 73
Study 37186772 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training during a standardized pulmonary rehabilitation program
Number of subjects: 73
Study 37186949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight loss and exercise intervention
Number of subjects: 0
Study 37186949 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dSL content in primary human myotubes
Number of subjects: 0
Study 37186949 — intervention group
Group type: EXPERIMENTAL
Intervention: dSL levels in muscle
Number of subjects: 0
Study 37187198 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (3 mg/m2)
Number of subjects: 588
Study 37187198 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (idarubicin, cytarabine, etoposide, ATRA)
Number of subjects: 588
Study 37187201 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy
Number of subjects: 80
Study 37187219 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session PCST protocol
Number of subjects: 327
Study 37187219 — intervention group
Group type: COMPARATOR
Intervention: 1-session PCST protocol
Number of subjects: 327
Study 37187219 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session PCST followed by 5 maintenance telephone calls for responders or 5 sessions of PCST for nonresponders
Number of subjects: 327
Study 37187329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting left ventricular ejection fraction (LVEF) ≤40%
Number of subjects: 584
Study 37187329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting infarction size (IS) ≥20% on the LV mass
Number of subjects: 584
Study 37187329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting microvascular dysfunction
Number of subjects: 584
Study 37187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Surgery (DS) in selected children undergoing R-RALP
Number of subjects: 32
Study 37187863 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CBT (online cognitive behavioral therapy)
Number of subjects: 0
Study 37187863 — intervention group
Group type: COMPARATOR
Intervention: In-person CBT
Number of subjects: 0
Study 37187863 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CBT
Number of subjects: 0
Study 37187878 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-enriched amino acid supplementation (6 g per day for 12 weeks)
Number of subjects: 22
Study 37187878 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-enriched amino acid supplementation and resistance exercise
Number of subjects: 22
Study 37188177 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS) testing and medical interpretation by a multidisciplinary molecular advisory board (MAB)
Number of subjects: 0
Study 37188177 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment program including educational workshops and videos about mBC and precision medicine
Number of subjects: 0
Study 37188309 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (twice a week for 8 weeks, 50 min each session)
Number of subjects: 0